HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.8%

Neg 0% Neu 91.8% Pos 0%

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics (NASDAQ:SLN) with a Buy and maintains $75 price target.